WO2025228255 - ACYLATED HUMAN INSULIN ANALOGUE
National phase entry is expected:
Publication Number
WO/2025/228255
Publication Date
06.11.2025
International Application No.
PCT/CN2025/091168
International Filing Date
25.04.2025
Title **
[English]
ACYLATED HUMAN INSULIN ANALOGUE
[French]
ANALOGUE D'INSULINE HUMAINE ACYLÉ
[Chinese]
酰化人胰岛素类似物
Applicants **
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Inventors
YU, Min
ZHANG, Chuanzhi
HUANG, Wenlong
WANG, Beihua
CHU, Xin
Priority Data
202410529560.X
28.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2242 | |
| EPO | Filing, Examination, Granting | 20728 | |
| Japan | Filing, Examination, Granting | 2709 | |
| South Korea | Filing, Examination, Granting | 3324 | |
| USA | Filing, Examination, Granting | 7340 |
Total:
36,343
Contact Us
Abstract[English]
The present application relates to the field of biomedicine, and specifically provides an acylated human insulin analogue, a pharmaceutical composition thereof and a preparation method therefor, and a method for using the acylated human insulin analogue or the pharmaceutical composition thereof to treat metabolic diseases.[French]
La présente demande relève du domaine de la biomédecine, et concerne en particulier un analogue d'insuline humaine acylé, une composition pharmaceutique de celui-ci et un procédé de préparation associé, ainsi qu'un procédé d'utilisation de l'analogue d'insuline humaine acylé ou de la composition pharmaceutique de celui-ci pour traiter des maladies métaboliques.[Chinese]
本申请属于生物医药领域，具体提供酰化人胰岛素类似物，其药物组合物和制备方法，以及使用所述酰化人胰岛素类似物或其药物组合物治疗代谢性疾病的方法。